Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Other operating expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Danaher

Danaher Corp. operates as a medical company, which designs, manufactures, and markets professional, medical, industrial, and commercial products and services. It operates through the following segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, to understand the causes of disease, identify new therapies and test new drugs and vaccines. The Diagnostics segment is composed of analytical instruments, reagents, consumables, software, and services that hospitals, physicians' offices, reference laboratories, and other critical care settings use to diagnose disease and make treatment decisions. The Environmental & Applied Solution segment offers products and services that help protect important resources and keep global food and water supplies safe. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Danaher exceeds Q1 expectations, eyes growth in China market

Danaher's Q1 performance showcased resilience and strategic focus amidst revenue challenges.
The company's strengths in operational efficiency and strategic initiatives position it well for future growth.
Challenges in certain segments highlight the need for adaptive strategies and market diversification.
Opportunities in China's market recovery and operational improvements offer avenues for sustained growth.

Danaher reports resilient Q2 performance amid COVID-19 challenges

Danaher navigated Q2 2023 with resilience amidst COVID-19 challenges, showcasing strong financial performance and strategic focus. While facing revenue declines in certain segments, the company remains confident in its ability to create shareholder value and improve human health. Capital deployment, inventory management, and market alignment present opportunities for future growth.

Danaher reports Q3 revenue decline, eyes growth in diagnostics market

Danaher's Q3 performance showed revenue declines in key segments, but strategic moves like spin-offs and acquisitions indicate a focus on long-term growth. Challenges in China and revenue projections for the year present short-term hurdles, while opportunities in drug development and diagnostics offer potential for future expansion.

Danaher reports solid 2023 performance, anticipates gradual growth in 2024

Danaher Corporation's 2023 performance showcased strong full-year sales and operating profit margin, but the fourth quarter saw a decline in core revenue. The company is focused on enhancing its portfolio and strengthening its growth trajectory, with expectations for improved growth in the second half of 2024. Challenges include the need for gradual improvement in demand and the pace of recovery in different geographies.

Danaher beats Q1 expectations, eyes growth in Diagnostics segment

Danaher's Q1 2024 performance exceeded expectations, driven by strong Diagnostics segment growth.
While facing challenges in bioprocessing and margin expectations, the company remains focused on long-term sustainability.
Opportunities lie in anticipated growth in Diagnostics and bioprocessing segments, with a focus on innovation and recurring revenue.
Continuous monitoring of market trends and global capabilities position Danaher for future success.

Danaher beats Q2 expectations, eyes growth amid revenue challenges

Danaher Corporation delivered a strong performance in Q2 2024, surpassing revenue, earnings, and cash flow expectations, driven by bioprocessing and Cepheid's success.
While facing challenges such as core revenue declines in the biotechnology segment, the company maintains a solid financial position with strong free cash flow.
Opportunities lie in leveraging positive momentum in key segments, expanding market share, and enhancing sustainability efforts to drive future growth and profitability.
Overall, Danaher's strategic focus on operational efficiency and growth areas positions it well to navigate challenges and capitalize on opportunities in the evolving market landscape.

Danaher surpasses Q3 expectations, eyes China stimulus for growth

Danaher's Q3 performance exceeded expectations, driven by strong results in biotechnology and Cepheid's core revenue growth.
While facing challenges in China market dynamics and core revenue declines in certain segments, the company remains optimistic about future growth.
Opportunities lie in leveraging China's stimulus for 2025 outlook and strategic M&A activities to fuel long-term growth and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. It operates through the following segments: Biotechnology, Life Sciences, Diagnostics, and Environmental and Applied Solutions. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a range of tools, consumables, and services. The Life Sciences segment offers a range of instruments and consumables to study the basic building blocks of life, including DNA and RNA. The Diagnostics segment offers clinical instruments, reagents, consumables, software, and services used to diagnose disease and make treatment decisions. The Environmental and Applied Solution segment offers products and services that help protect important resources and keep global food and water supplies safe. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC.

Shares dipped after the recent earnings results, but it doesn't appear to be anything to worry about.

Is Danaher Still a Great Stock for a Retirement Portfolio?

Narrowly beating Wall Street estimates and lowering its full-year outlook didn't excite investors, but a big acquisition is on the way that could generate plenty of excitement.

What You'll Want to Know About Danaher's Q3 Earnings Results

Danaher Corporation (DHR) CEO Thomas Joyce, Jr. on Q3 2019 Results - Earnings Call Transcript

Danaher's (DHR) third-quarter 2019 earnings benefit from organic sales growth, acquisitions and DBS initiatives. It lowers 2019 projection, accounting for the Envista transaction.

Danaher (DHR) Beats Q3 Earnings Estimates, Lowers '19 View

Shares of Danaher Corp. DHR, +1.00% fell 1.6% in premarket trading Thursday, after the medical technology and products company beat profit and revenue expectations, but provided a downbeat earnings outlook.

Danaher's stock drops after downbeat outlook offsets profit beat

Danaher (DHR) delivered earnings and revenue surprises of 0.87% and -0.06%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Danaher (DHR) Q3 Earnings Surpass Estimates

Danaher's (DHR) third-quarter earnings are expected to reflect the impact of Danaher Business System, acquired assets, solid product offerings and innovation. Forex and cost woes remain.

Can Danaher (DHR) Keep Earnings Beat Streak Alive in Q3?

American Express

QUALCOMM

Toronto-Dominion Bank

According to the GuruFocus All-In-One Screener as of Wednesday, the following companies look cheap since they are trading with low price-sales ratios.

6 Stocks Trading With Low Price-Sales Ratios

Danaher (DHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Danaher (DHR) Reports Next Week: Wall Street Expects Earnings Growth

Danaher (DHR) Earnings Expected to Grow: What to Know Ahead of Q3 Release

Danaher (DHR) intends to redeem $875 million worth of senior notes. Funds received from Envista will be used for note redemption.

Danaher (DHR) Plans to Redeem $875M Worth of Senior Notes

Danaher's (DHR) Envista closes its initial public offering and pays the proceeds to Danaher as part payment for its assets.

Danaher's (DHR) Subsidiary Envista Closes IPO, Shares Up

Agilent Technologies

General Electric

Thermo Fisher Scientific

Increased use of reagents in the field of research, bioscience and genetics is pushing the biotechnology reagents market higher.

4 Stocks to Focus on Global Biotechnology Reagents Market

Danaher's (DHR) subsidiary, Envista, goes public with an initial offering of roughly 26.8 million shares.

Danaher's Subsidiary Envista Prices IPO, to Trade as NVST

United Technologies

UTX vs. DHR: Which Stock Is the Better Value Option?

UTX or DHR: Which Is the Better Value Stock Right Now?

Danaher's (DHR) subsidiary prices euro 6.25 billion worth of senior notes offerings. The net proceeds will be used for paying for the pending acquisition of General Electric's BioPharma business.

Danaher's Senior Notes Offerings to Fund BioPharma Buyout

Have you ever dreamed of being that one in a million investor who has the talent to perfectly time the markets?

Simple Market Timing Strategies That Work - September 02, 2019

Danaher (DHR) outperforms its industry and the S&P 500 year to date on solid financial performances, buyout gains, solid product demand, shareholder-friendly policies and other factors.

Danaher (DHR) Stock Rises 38% YTD: What's Driving the Rally?

The economy may be slowing but there are still pockets of growth for investors to exploit.

Here's Why the Best Is Yet to Come for Danaher

Danaher's (DHR) solid product portfolio and focus on innovation are boons. However, rise in costs and expenses as well as high debts and forex woes are concerning.

Danaher Gains From Rising Product Demand Despite High Costs

Danaher (DHR) reported earnings 30 days ago. What's next for the stock?

Danaher (DHR) Down 1.9% Since Last Earnings Report: Can It Rebound?

UTX vs. DHR: Which Stock Should Value Investors Buy Now?

The stock is a safe place to hide in an uncertain environment.

Danaher Remains on Track in 2019

EVP of Danaher Corp (30-Year Financial, Insider Trades) Daniel L Comas (insider trades) sold 68,379 shares of DHR on 07/19/2019 at an average price of $142.05 a share.

Danaher Corp (DHR) EVP Daniel L Comas Sold $9.7 million of Shares

Danaher’s total return over-performed the Dow average for my 55 month test period by 64.21%, which is great for a company that has increased revenues, earnings, and dividends.

News for Danaher Stock (DHR)